Imeglimin-d3

Imeglimin-d3 (EMD 387008-d3) is deuterium labeled Imeglimin. Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function[1].

Product Specifications

Product Name Alternative

EMD 387008-d3

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Mitochondrial Metabolism; Reactive Oxygen Species (ROS)

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Smiles

CN(C1=NC(C([2H])([2H])[2H])=N[C@@H](C)N1)C

Molecular Formula

C7H11D3N4

Molecular Weight

157.23

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Vial G, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrialfunction in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015 Jun;64 (6) :2254-64.|[3]Detaille D, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072.